Making strides in GVHD patient care: The power behind a winning idea
Feb. 3, 2021
FacebookTwitterEmail
(BPT) - For individuals living with blood cancer, stem cell transplantation can offer a potential cure. Over the last decade, survival rates for patients who receive such transplants have been improving. However, for a small group of these patients, an allogenic stem cell transplantation may result in another disease called graft-vs-host disease (GVHD), a potentially fatal complication that can appear after stem cell transplantation.
GVHD, which can be an acute or chronic condition, marks the start of an unexpected journey for these patients and their caregivers. It is with this in mind that Incyte launched the Incyte Ingenuity Award, which funds innovative initiatives to address the unique needs of the US GVHD community.